642 692
[94]
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzaluta- mide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97.[95]
Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA. Evi- dence-based standards for cancer pain management. J Clin Oncol 2008;26:3879–85.[96]
Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798–804.
[97]
Saad F, Gleason DM, Murray R, et al. A randomized, placebo- controlled trial of zoledronic acid in patients with hormone- refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–68.[98]
Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an inter- national expert panel. Ann Oncol 2008;19:420–32.[99]
Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metas- tasis-free survival in men with castration-resistant prostate can- cer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39–46.[100]
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration- resistant prostate cancer: a randomised, double-blind study. Lan- cet 2011;377:813–22.
[101]
Esper PS, Pienta KJ. Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol 1997;15:56–64.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 3 0 – 6 4 2
642